SAN FRANCISCO — In a historic milestone for neurotechnology, Coherence Neuro—a San Francisco-based longevity startup with close ties to Elon Musk’s Neuralink—has commenced human testing of a specialized brain implant designed to detect and disrupt cancer.
According to a report by Wired, the company successfully tested its flagship device in three consenting patients, marking the first time a brain-computer interface (BCI) has been utilized specifically to track and treat aggressive intracranial tumors.
The Initial Human Trials
The initial clinical trial focused on glioblastoma, a notoriously aggressive and terminal form of brain cancer.
To test acute safety and signal clarity, surgeons briefly placed the button-sized implant into the brains of three patients who were already undergoing surgical procedures for tumor removal. The device remained active for approximately 30 minutes to gather data before being carefully extracted. By targeting glioblastoma, Coherence Neuro hopes to transform terminal oncological care from a cycle of brutal, systemic interventions into a continuously monitored, seamlessly managed condition.
Disrupting Cancer’s Bioelectrical Network
The underlying science behind the device relies on groundbreaking medical research revealing that cancer tissue operates as an electrically active entity. Aggressive brain tumors actively hijack the bioelectrical signals of surrounding healthy brain tissue to accelerate their own growth.
Coherence Neuro’s proprietary hardware system, named SOMA, is engineered to intercept this hijacking process through a dual-action mechanism:
- Read: The micro-implant reads the subtle, hyper-specific electrical properties of malignant masses.
- Disrupt: It simultaneously emits targeted electrical stimulation intended to stave off tumor development.
The internal implant pairs with a coin-sized external wearable worn over the ear and a mobile application. This allows clinicians to remotely monitor real-time neural data and adjust therapeutic stimulation without requiring patients to make exhausting, repetitive hospital visits.
The Neuralink Connection and Future Frontiers
Founded in 2022 by engineering doctorates Ben Woodington and Elise Jenkins, Coherence Neuro boasts deep structural links to Elon Musk’s high-profile neurotech ecosystem. Neuralink’s head neurosurgeon serves as an active adviser and investor in the startup, and key investigators from Neuralink’s trials are slated to spearhead Coherence’s upcoming long-term clinical studies.
While previous bioelectric companies have created external wearables to help prolong the lives of glioblastoma patients, Coherence Neuro’s direct cortical approach is far more precise. The development team maintains that if these intracranial trials prove successful, the core biophysical principles governing SOMA could eventually be adapted to intercept and treat cancer varieties throughout the entire human body.